Recent corporate updates from Bicycle Therapeutics (NASDAQ: BCYC) center around the clinical progress of its proprietary bicyclic peptide (Bicycle) drug candidates targeting various oncology indications, alongside strategic pipeline prioritizations. Following previous workforce optimization phases designed to manage operating expenditures efficiently, the company continues to collaborate with major pharmaceutical partners to advance novel tumor-targeted treatments through clinical phases, focusing on expanding its therapeutic reach while maximizing its clinical trial cash runway.